Sivia Capital Partners LLC Invests $29,000 in Gossamer Bio, Inc. (NASDAQ:GOSS)

Sivia Capital Partners LLC acquired a new stake in Gossamer Bio, Inc. (NASDAQ:GOSS) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 24,568 shares of the company’s stock, valued at approximately $29,000.

Several other hedge funds have also added to or reduced their stakes in the stock. Financial Advocates Investment Management increased its holdings in Gossamer Bio by 35.0% during the 4th quarter. Financial Advocates Investment Management now owns 98,350 shares of the company’s stock worth $90,000 after acquiring an additional 25,500 shares during the period. Citigroup Inc. boosted its position in shares of Gossamer Bio by 9,916.9% during the 3rd quarter. Citigroup Inc. now owns 196,732 shares of the company’s stock valued at $164,000 after acquiring an additional 194,768 shares during the last quarter. Kynam Capital Management LP purchased a new position in shares of Gossamer Bio during the third quarter worth about $208,000. Monaco Asset Management SAM bought a new stake in Gossamer Bio during the fourth quarter valued at approximately $256,000. Finally, Victory Capital Management Inc. grew its stake in Gossamer Bio by 1,402.4% in the 4th quarter. Victory Capital Management Inc. now owns 312,357 shares of the company’s stock worth $285,000 after buying an additional 291,566 shares in the last quarter. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Stock Up 1.2 %

NASDAQ:GOSS traded up $0.01 during mid-day trading on Wednesday, reaching $0.97. The company’s stock had a trading volume of 952,189 shares, compared to its average volume of 1,725,086. Gossamer Bio, Inc. has a 1 year low of $0.45 and a 1 year high of $1.88. The company has a quick ratio of 7.13, a current ratio of 7.13 and a debt-to-equity ratio of 7.37. The stock has a fifty day moving average of $0.68 and a 200-day moving average of $0.92.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.19). Sell-side analysts predict that Gossamer Bio, Inc. will post -0.41 EPS for the current year.

Insider Buying and Selling at Gossamer Bio

In other Gossamer Bio news, CEO Faheem Hasnain purchased 372,000 shares of the stock in a transaction on Friday, June 21st. The shares were bought at an average price of $0.67 per share, for a total transaction of $249,240.00. Following the completion of the transaction, the chief executive officer now owns 5,408,073 shares of the company’s stock, valued at approximately $3,623,408.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.00% of the company’s stock.

Wall Street Analysts Forecast Growth

GOSS has been the subject of a number of analyst reports. Wedbush reiterated an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a report on Wednesday, May 8th. Oppenheimer initiated coverage on shares of Gossamer Bio in a research note on Tuesday, June 25th. They set an “outperform” rating and a $9.00 price objective on the stock. The Goldman Sachs Group restated a “buy” rating and issued a $8.00 price target on shares of Gossamer Bio in a research note on Monday, June 17th. Piper Sandler reissued an “overweight” rating and issued a $15.00 target price on shares of Gossamer Bio in a research note on Wednesday, March 27th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research report on Monday, May 20th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Gossamer Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.88.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.